The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia



Summary

Social determinants of health (SDOH) significantly impact outcomes in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) receiving brexucabtagene autoleucel (brexu-cel). Studies show patients with lower socioeconomic status, limited access to care, food insecurity, and inadequate housing experience higher rates of treatment-related toxicities (like cytokine release syndrome and neurotoxicity), lower rates of complete remission, and shorter overall survival after brexu-cel infusion. Addressing these SDOH through targeted interventions and supportive care is crucial to improve access, mitigate disparities, and optimize the effectiveness of brexu-cel in this vulnerable patient population.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!